Resistomycin (Geliomycin), a pentacyclic polyketide antibiotic, exhibits potent anticancer properties by triggering apoptosis.

Resistomycin effectively impedes the advancement of triple-negative breast cancer (TNBC) by targeting and inhibiting E3 ligase Pellino-1, which leads to the degradation of SNAIL/SLUG proteins. It binds strongly to GST-Pellino-1, with a dissociation constant (KD) of 2.58 μM, as demonstrated through surface plasmon resonance [1]. Additionally, Resistomycin administration has been shown to decrease SNAIL and SLUG protein levels in TNBC cells [1]. Furthermore, it has been found to provoke apoptosis and cell cycle arrest in human hepatocellular carcinoma cells by activating the p38 MAPK pathway, both in laboratory settings and in animal models [2].